Effects of Aerobic Exercise Intensity on Clinical & Neural Outcomes in Depressed Youth
NCT ID: NCT04110041
Last Updated: 2024-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
40 participants
INTERVENTIONAL
2018-08-07
2025-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Aerobic Exercise Modulation on Brain Physiology and Cognition in Young Adults With Depression
NCT04708691
Cognitive Benefits of Aerobic Exercise Across the Age Span
NCT01179958
Exercise Intensity on Brain & Mental Health in Stress
NCT06245538
Aerobic Group Exercise for Adolescents With Depression
NCT04695145
Effects of Aerobic Exercise on Cognitive Function and Brain-derived Neurotrophic Factor in Young Adults
NCT02075944
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives: The primary objectives of this study are: 1) to determine the effects of moderate vs. high intensity AE on clinically-rated and subjective symptoms of MDD in TAY; and 2) to examine the psychosocial, cognitive, and neuromodulatory effects of these interventions.
Methods: This two-arm, randomized trial will recruit 40 TAY (16-24 yrs) with MDD/persistent depressive disorder (PDD) into one of two AE intensity groups: medium or high. Intensity is defined as a percentage of heart rate reserve (HRR) achieved during exercise, as outlined in the American College of Sports Medicine (ACSM) guidelines (moderate: 50-55% of HRR; N=20; high: 80-85% HRR; N=20). All participants will undergo supervised and guided AE intervention sessions (\~30min), three times per week, for twelve consecutive weeks. Pertinent clinical and psychosocial scores, as well as cardiac function (as assessed by maximal oxygen consumption \[VO2max\]), will be recorded pre-intervention (Week 0), mid-intervention (Week 6), and post-intervention (Week 12). Additionally, participants will undergo electroencephalographic (EEG) and functional magnetic resonance neuroimaging (fMRI) before and after the completion of AE intervention. Specifically, neural dynamics will be recorded at rest and during cognitive tasks engaging working memory (N-Back task) and response inhibition (Flanker task) - cognitive abilities, which have been shown to be impaired in MDD in TAY. Both clinical/psychosocial and neuroimaging outcomes will be compared using time as the within-group, and intervention type as between-group factors.
Hypotheses: The investigators expect a significant reduction in depression symptoms post (vs. pre) intervention and, based on preliminary evidence in adults, a greater reduction may emerge in those participating in the high (vs. moderate) intensity AE. Further, the investigators expect changes in fMRI profiles from pre- to post-intervention (showing normalization of brain activity and connectivity profiles); the same is true of EEG/event-related potential (ERP) features. They also expect a positive relation between VO2max and brain-based changes.
Significance: Findings from this project will help guide future large-scale investigations of AE as a potential treatment for TAY by clarifying the relation between changes to physical indices, depressive symptoms and neural profiles. Importantly, identifying the brain features modulated by AE will broaden our understanding of the neurobiological markers underlying depressive states, allowing for targeted therapeutic approaches and better outcomes for TAY suffering from MDD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Moderate Intensity
Aerobic exercise maintained for 30 minutes at 50-55% of each participant's individual heart rate reserve (HRRes).
Aerobic Exercise
Thrice-weekly aerobic exercise sessions lasting \~45 minutes, for 12 consecutive weeks.
High Intensity
Aerobic exercise maintained for 30 minutes at 80-85% of each participant's individual heart rate reserve (HRRes).
Aerobic Exercise
Thrice-weekly aerobic exercise sessions lasting \~45 minutes, for 12 consecutive weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aerobic Exercise
Thrice-weekly aerobic exercise sessions lasting \~45 minutes, for 12 consecutive weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Free of pharmacotherapy (ie. antidepressant medication) for \>5 weeks;
* Not currently engaging in regular moderate or vigorous intensity exercise;
* Able to read/understand English;
* Body mass index \[BMI\] \< 40;
* Medically cleared to engage in aerobic exercise.
Exclusion Criteria
* Another Axis I/II DSM-5 disorder, apart from co-morbid anxiety disorder(s);
* Current or lifetime history of serious medical or neurological conditions;
* Currently taking psychoactive drugs (occasional use of anti-anxiety medication permitted);
* Regular user of nicotine products;
* Unstable medical conditions, especially those that prevent exercise;
* Exhibiting significant suicide risk;
* MRI contraindications;
* Currently pregnant or breastfeeding.
16 Years
24 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Royal's Institute of Mental Health Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Natalia Jaworska
Director, Clinical Electrophysiology Laboratory
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Ottawa Institute of Mental Health Research
Ottawa, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.